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Background. Few data have been published regarding long-term mortality in patients with Parkinson’s disease treated with DBS.
Methods. This study analyzed long-term mortality rates, causes, and correlates in PD patients treated with DBS. Results. 184
consecutive patients were included; mean follow-up was 50 months. Fifteen deaths occurred (total 8.15%, annual mortality rate
1.94%). Mean age at disease onset and at surgery was 48 ± 2.4 and 63 ± 1.6 years, respectively. Mean disease duration until death
was 21 ± 7.8 years. Most deaths related to stroke, myocardial infarction, other vascular/heart disorders, or severe infection; one
suicide was recorded. Deceased PD patients were mostly male and had lower motor benefit after DBS, but univariate analysis failed
to show significant differences regarding gender and motor benefit. Survival was 99% and 94% at 3 and 5 years. Conclusions. Long-
term survival is to be expected in PD patients treated with DBS, possibly higher than previously expected. Death usually supervenes
due to vascular events or infection.
1. Introduction
Parkinson’s disease is a common, disabling neurodegenera-
tive disorder. Motor symptoms and quality of life improve
significantly under adequate treatment, althoughmotor com-
plications commonly arise, typically a few years after the
onset of dopaminergic therapy [1]. Several studies have
looked into mortality in PD and found a higher risk of
death as compared to the general population, even after
the introduction of levodopa [2, 3]. Deep brain stimulation
(DBS) is an effective procedure in Parkinson’s disease (PD)
with motor complications [4]. It is safe and surgery-related
mortality is low [5]. However, little is known about the long-
term mortality in this population, in particular regarding
death rates and causes, as few data have been published [6–
8]. The recent publication of the EARLYSTIM trial results
emphasizes the importance of analyzing this issue in depth,
as the number of candidates for DBS will predictably increase
in the near future [9].The aims of this research paper were to
evaluate the rates and causes of death in PD patients treated
with DBS, up to ten years after surgery.
2. Patients and Methods
Patients enrolled in this study had been consecutively sub-
mitted to DBS at the Movement Disorders and Functional
Surgery Unit of a large University Hospital between October
2002 and November 2012. All patients were examined before
and one month after surgery and then every 6 months. Uni-
fied Parkinson’s Disease Rating Scale (UPDRS) was assessed
before surgery with and without L-dopa medication. After
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the procedure UPDRS was determined, with stimulation
turned on and off. Behavior, mood, activities of daily living,
disability, and complications from therapy were assessed
using UPDRS (parts I, II, and IV), Schwab and England
scale, Beck Depression Inventory, and Geriatric Depression
Scale. All patients underwent a comprehensive neuropsy-
chological evaluation prior to surgery and postoperatively at
6 months, 18 months, and 5 years. Neuropsychological test
batteries were administered by a trained neuropsychologist.
Instruments included the Mini-Mental State Examination,
the Frontal Assessment Battery, the Clock Drawing Test,
the Dementia Rating Scale, verbal fluency (semantic and
phonemic), digit span, associative verbal memory, and visual
memory tasks from the Wechsler Memory Scale, the Stroop
Test, the Trail Making Test, and the Wisconsin Card Sorting
Test. All cognitive assessments before and after surgery were
performed while the patients were at a state of pragmatically
defined “on.” Postoperative assessments were performed with
the stimulators turned on. Adverse events following surgery
(including date and cause of death) were recorded during
the inpatient period and at each outpatient visit. In addition,
general demographic (e.g., age, gender) and clinical data (e.g.,
disease duration, phenotype, medication type, and dosage)
were documented for each patient.
Widely accepted standard inclusion and exclusion criteria
for DBS have been observed [10, 11], All subjects met the
following criteria: (i) Parkinson’s disease diagnosed according
to the United Kingdom Parkinson’s Disease Society Brain
Bank criteria (in our patients the diagnosis had been estab-
lished for at least 5 years); (ii) at least 50% improvement in
motor symptoms after an acute levodopa challenge following
complete medication withdrawal for at least 12 hours; (iii)
troublesomemotor fluctuations anddyskinesias, despite opti-
mal medical therapy adjusted by expert in PD; (iv) clinical
examination fully consistent with PD; (v) age up to 70 years,
with some degree of flexibility; (vi) absence of dementia or
major uncontrolled psychiatric disorders, including suicidal
ideation; (vii) absence of neurosurgical, neuroradiological, or
general medical contraindications.
Data used in this study concerns follow-up until death or
November 2012. No patient was lost to follow-up. Causes of
death were determined from confirmed clinical data, except
in one patient in whom autopsy was carried out.
Kaplan-Meier survival curves were constructed using
death (any cause) as the endpoint. Beyond a descriptive
analysis, we performed a comparative analysis using Cox
regression to assess differences by gender, disease type, age
at motor symptom onset, age at the time of surgery, disease
duration until surgery, UPDRS before surgery with and with-
out L-dopa medication, and motor benefit one month after
surgery. A descriptive, comparative, and survival analysis was
performed, using STATA and SPSS (version 20.0).
3. Results
Between October 2002 and November 2012, 184 PD patients
were treated with bilateral deep brain stimulation (181 sub-
thalamic nuclei, 3 globus pallidus internus). Fifteen deaths
occurred during the follow-up period (mean 50 months,
global mortality 8.15%, and annual mortality rate 1.94%),
none of which occurring within the first month after surgery.
3.1. Characteristics of the Whole PD Population Treated with
DBS. Sixty-one percent of PD patients treatedwithDBSwere
men (𝑛 = 113). Mean age at disease onset was 47 ± 9 years
(18–64) and mean age at surgery was 60 ± 8 years (33–73).
Mean disease duration until surgery was 14 years (5–48).
Sixty percent of patients (𝑛 = 111) presented akinesia and
rigidity as the main disease motor symptoms. Presurgical
UPDRS part III average score was 46 ± 11 off medication
and 15 ± 7 at the best on state. The average motor benefit
in the first month after surgery, based on UPDRS part III
before surgery without medication and UPDRS part III after
surgery on stimulation and off medication, was 74 ± 14%.
There were no significant differences between STN and GPi
stimulated patients regarding demographic data, UPDRS
scores, or levodopa responsiveness.
3.2. Characteristics of Deceased Patients. Mean age at disease
onset and at the time of surgery was 48 ± 2.4 (28–59) and
63 ± 1.6 years (51–71), respectively. Mean disease duration
until surgery and until death was 15 ± 1.6 (7–35) and 21 ± 7.8
(11–35) years, respectively. All deceased patients had received
subthalamic DBS. Average time elapsed between surgery and
death was 65 ± 33.1 months (min 2; max 115), and mean age
at the time of death was 67 ± 6.3 (54–76) years. Preoperative
UPDRS-III average score was 46 (33–62) off medication and
12 (7–20) at the best on state. The mean motor benefit one
month after surgery was 62% (46–85).
Eight of the deceased patients (53%) had clinical criteria
for dementia [12], at least at the last observation. Table 1
shows the comparison between deceased and alive patients,
regarding baseline features. Deaths were mostly attributed to
vascular events (𝑛 = 6) and respiratory infections (𝑛 = 5); one
suicide occurred 39 months after surgery (Table 2). Deceased
PD patients were mostly men (𝑛 = 13 or 87% of total deaths,
𝑃 = 0.032) and had gained less motor benefit from surgery
(62% versus 76%, 𝑃 = 0.0004). However, univariate analysis
(Cox regression and Kaplan-Meier survival analysis) did not
show significant differences regarding gender (HR = 3.740,
𝑃 = 0.083; IC 95% (0.840–16.654)) or motor benefit (cut-
off at 70%: HR = 1.685, 𝑃 = 0.362; IC 95% (0.549–5.174))
between deceased and nondeceased groups (Figures 1 and 2).
Age at surgery higher than 65 years correlatedwith higher
mortality risk (HR= 3.053,𝑃 = 0.040; IC a 95% (1.53–8.849)).
Survival in this series was 99% at 3 years, 94% at 5 years, and
88% at 7 years after surgery (Figure 3).
4. Discussion
To the best of our knowledge this is the largest series
published so far analyzing long-term mortality in DBS-
treated PD patients [4, 6–8, 13].
Survival in this series seems somewhat higher than
previously reported (Toft et al. found survival rates of 97%
at 3 years and 90% at 5 years; Schüpbach et al. reported 97%
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Table 1: Comparison between deceased patients and survivors.
Deceased patients Nondeceased patients 𝑃 value
Male gender: 𝑛 (%) 13 (86.67) 100 (59.17) 0.032
Age at disease onset (mean, years) 48.07 ± 2.41 46.74 ± 0.69 0.707
Akinetic-rigid phenotype: 𝑛 (%) 8 (53.33) 103 (60.95) 0.564
Age at the time of DBS (mean, years) 62.8 ± 1.62 60.23 ± 0.59 0.894
Disease duration until DBS (mean, years) 14.53 ± 1.59 13.42 ± 0.46 0.751
UPDRS part III before surgery without L-dopa medication (mean) 45.6 ± 2.09 46.34 ± 0.84 0.399
UPDRS part III before surgery with L-dopa medication (mean) 12.47 ± 1.20 14.90 ± 0.51 0.083
Motor benefit after surgery (mean, %) 62.4 ± 5.26 75.52 ± 0.96 0.0004
Table 2: Deceased PD patients treated with DBS. M: male, F: female.
Patient Gender Time between surgeryand death (months) Cause of death Comorbidities
1 M 48 Metastasized colon cancer HypertensionIschemic stroke
2 F 45 Myocardial infarction Urinary lithiasis




4 M 69 Peritonitis, sepsis Kidney cancerDementia
5 M 39 Suicide —
6 M 38 Hemorrhagic stroke DyslipidemiaDementia
7 M 108 Hemorrhagic stroke Prostatic cancer
8 F 76 Traumatic brain injury DepressionDementia




10 M 115 Pneumonia —
11 M 26 Myocardial infarction Herniated cervicaldisk





13 M 111 Pneumonia Ischemic strokeDementia
14 M 2 Cardiomyopathy —




at 2 years and 89% at 5 years), although it is not possible to
calculate whether the difference is significant [6–8]. Anyway,
the annual mortality rate reported in this series is clearly
lower than that described by Wider et al. (8.5%) [8].
Mean age at death (67 years) was higher than that
reported by Schüpbach et al. (63 years), although our patients
had a higher mean age at surgery (60 versus 57 years) and a
slightly higher mean disease duration until surgery (14 versus
13 years) [7]. The mean follow-up time between surgery and
death (65 months) was also higher than previously described
(Wider et al. 42 months, Schüpbach et al. 45, and Toft
et al. 42) [6–8]. Taken altogether, our results suggest that
survival followingDBS inPDmight be higher than previously
estimated.
In this series, age at surgery above 65 years seems to be
a predictive mortality factor, as reported by other authors
[6, 8]. However, we find ourselves unable to relate this
finding to the procedure, and this could be due to natural
history only (i.e., older patients are at higher risk of death
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Figure 1: Survival of PDpatients by gender. Cox regression indicates
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Figure 2: Survival of PD patients by motor benefit following DBS.
Cox regression indicates no statistical difference between groups.
not different between deceased and nondeceased patients, in
contrast to the results reported by Toft et al., who found a
relationship between mortality and higher UPDRS score off
medication preoperatively [6]. Age at disease onset, disease
duration until surgery, and the phenotype of the disease were
also not different between groups. Our PD deceased patients
were mostly men, which parallels with previously published
data reporting greater mortality in male PD patients who did
not have DBS [14]. Moreover, deceased patients had lower
motor benefit one month after surgery (62% versus 76%,
𝑃 = 0.0004). One might speculate that axial symptoms in
these patients could be more severe thus predisposing to
falls, but only one death (out of 15) was related to falling.
Otherwise, there were no statistically significant differences
between deceased and nondeceased groups with regard to
gender or motor benefit. Also, it is not possible to accurately
compare STN and GPi groups in this series, due to the very
small number of patients in the latter (181 versus 3).
In this series infection was a common cause of death,
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Figure 3: Kaplan-Meier survival curve for the studied population.
with published studies describing pneumonia as an impor-
tant cause of death in PD [2, 14]. In our series there were no
deaths within the first month after surgery, nor any deaths
related to the procedure or hardware complications, which
stands in agreement with known DBS safety data. There
was one suicide (0.54% of all DBS cases), which stands in
accordancewith the results from the largestmulticenter study
published so far on this topic in DBS-treated PD patients [15].
Of note, most deceased patients in this study fulfilled
criteria for dementia, which has been associatedwith a higher
mortality risk in PD [16].
Our study is limited by the absence of a control group
of clinically similar PD patients who did not have DBS (e.g.,
due to patient refusal to have surgery), in order to compare
survival and death causes. Nonetheless, we feel intrigued
by the fact that long-term survival seems relatively high
for a population of advanced PD patients with long disease
duration and wonder whether DBS has any positive effect on
survival in PD.
In summary, we found that long-term mortality rates
might be lower than previously estimated, and high survival
rates are to be expected following DBS in PD, despite the fact
that patients already present motor complications and long
disease duration at the time of surgery. Mortality is higher
among PD male patients or those gaining less motor benefit
from surgery, although neither gender nor motor benefit
seems to predict death. Older age at surgery correlates with
mortality, but this cannot be associated with the procedure
itself, and could be simply related to the fact that older people
are at higher risk of death. Death in these patients is largely
unrelated to PD or surgical complications, as vascular events
and pneumonia lead the causes, which stands in line with
published epidemiological data in PD. Future research studies
should prospectively assess the effect of DBS on patient
survival in PD, as compared to best medical therapy.
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